NAROPIN vs bupivacaine
Learn more about the benefits of NAROPIN.
The Fresenius Kabi USA Medical Affairs Department strives to educate the medical and lay communities concerning the safe and efficacious use of its products. Medical Affairs also strives to protect the public’s health and safety through the collection of, investigation into, and reporting of data pertaining to the safety and quality of its products. Medical Affairs professionals are available Monday through Friday, 8 AM–5 PM (CST).
Toll-Free: (800) 551-7176 (option 3)
Fax: (847) 550-7121
Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs. NAROPIN may be associated with adverse reactions which are characteristic of those associated with other amide-type local anesthetics.1 In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information.
1. NAROPIN Prescribing Information Data on file.
NAROPIN is indicated for the production of local or regional anesthesia for surgery and acute pain management.
NAROPIN and logo are registered trademarks of Fresenius Kabi USA, LLC. ©2015, Fresenius Kabi USA, LLC. All Rights Reserved.